

10th February 2011

MPH AG expands product portfolio

Cost savings also in new therapy areas

Berlin, 10th February 2011 – The expanding pharmaceuticals and health corporation MPH has achieved more than two thirds of the turnover with products in the oncological field in both the past years.

The company however continues to grow. Characteristic for the expansion is the effect of new and important licences in the therapeutic areas HIV, neurology, heart and circulatory diseases and rheumatic diseases. And the new figures speak for themselves: the status in December 2010 is that only somewhat more than half of the product portfolio is in the area of oncology. So apart from the most common pharmaceutical products for cancer treatment, the further product range is also a driver for the continuous growth.

“We feel obliged to contribute towards continuing to make health affordable” explains Management board member Dr. Christian Pahl. “The longer life expectancy and also chronic diseases lead to an increasing requirement for medicinal products that need to be taken life long. Through generics and EU brand pharmaceutical products, cost savings can be effectively achieved. The beneficiaries of this cost reduction are primarily the health insurance providers and thereby the premium payers.

Through the processing of further therapeutic areas we want to increase the contribution towards cost savings and further develop the utility for the general public.”

About the MPH Mittelständische Pharma Holding AG:

The Berlin-based MPH Mittelständische Pharma Holding AG has concentrated itself strategically on growth segments in the pharmaceutical market. The core competences are in the area of procurement, manufacture and licensing of pharmaceutical products. Together with the subsidiary company HAEMATO PHARM AG, the business areas of development and acquisition of marketing authorisation for generics, as well as licensing and imports of European brand pharmaceutical products are currently being covered. The product range comprises of the oncological area and the therapeutic areas HIV, neurology, heart and circulatory diseases, as well as rheumatic diseases and is being continuously expanded.

Press release



10th February 2011

At present the company employs roughly 54 employees and in 2010 achieved a turnover of more than EUR 100 million.

The company MPH Mittelständische Pharma Holding AG is listed in the Open Market of the Frankfurt stock exchange (WKN: A0NF69).

Contact:

MPH Mittelständische Pharma Holding AG
Patricia Blechinger
Hubertusallee 73
14193 Berlin
Tel: 030 / 897 308 660
p.blechinger@mph-ag.de
www.mph-ag.de